A strategy that integrates growth in the US market, expansion of the pharmaceutical pipeline and business rationalization in anticipation of the end of Radicava's exclusive sales period. Following the transfer of the business to Mitsubishi Tanabe Pharma, its classification changed from continuing operations to discontinued operations.